Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How so? I too had low expectations but was pleasantly surprised and pleased with the additional clarifications and direct comparisons to lecanemab and aduhelm!
Disingenuous would be portraying the company as incapable of doing basic math when in actually they have already responded to this. You know this but choose to ignore it because it does not align with your narrative.
From Anavex IR:
"Not an error, these are because there are not the same numbers of patients for every visit.
The mean of change from baseline is not equivalent to subtraction of baseline scores from end of treatment scores when all patients do not have both measures."
Agreed!
Agreed, hopefully the damage was minimal. Came so close to finally having a clean, concise press release for once!
The original PR posted to the Anavex site said "7%" RSBQ response instead of "66.7%", and a "7%" CGI-I response instead of "86.7%". The Anavex team was notified of these errors and they've since been corrected.
Sounds like we might disagree but that's cool...we're all mature enough to make our own decisions based on the facts on the table. All I ask is that you don't spread misinformation about endpoints please.
Agreed. It's Biogen paying to drive excitement and put more pressure on the FDA. Found this in a Motley Fool article published 2 days ago:
Ever since Biogen (NASDAQ:BIIB) revived a phase 3 Alzheimer's program a year ago, investors have been waiting with bated breath for the next steps. The company submitted aducanumab, the investigational Alzheimer's treatment, for regulatory review in July. Now, an advisory committee is set to meet on Nov. 6 to weigh in on whether the U.S. Food and Drug Administration (FDA) should approve the drug candidate.
https://www.fool.com/investing/2020/10/27/why-an-upcoming-fda-meeting-is-critical-for-biogen/
Where are you guys seeing 3 years? The latest March presentation says 2?
Excellent post, thanks. Any chance you could please elaborate on the recent patent accomplishments? As far as I know, we're still not very well protected yet for the use of 2-73 on its own (not combined with donepezil). Unless there have been any updates I missed?
The 2 upcoming trials are definitely exciting, but does anyone have any idea how the company plans to fund them? This has been, and continues to be, my largest concern as an OBMP shareholder...
Lol thanks for the scare tactics
What's the recent news?
Well said! Let's hope management can deliver on their word soon so we can sustain today's growth and continue our strong upward momentum.
Ah yes, 10 k, my mistake!
The 10-Q is published on the company's website for those eager to read. I'll be honest, it wasn't a very positive read for me personally. Funding remains an enormous concern, and the losses this past fiscal year, including loss of the Vitel agreement, were substantial. I'm really concerned how the company will pay for any upcoming trial given their awful cash position. Would love to hear everyone's thoughts! Been an investor since April 2016. Thanks
Hey GM26, what do you mean by pipeline results? Is the company planning to update their pipeline with new information vs what is included in their March 2018 investor deck?
I've been an AVXL long since Jan 2015 but truthfully have a lot of trouble seeing a $100 share price by 2019. At this point, I'll be happy to see a double digit sp given the continued lack of shareholder communication and transparency. The past 12 months have been downright embarrassing if I'm being honest.
Patience pays off...hopefully more big news coming in the next few months too. Cheers!
You betcha
Yep, for A.B. Labs...still awaiting Acreage Farms. Great start!!
SALES LICENSE!!!! BOOM!!!!
https://imgur.com/a/rL8yy
I've heard this same early Feb license timing from other companies too, thanks for sharing.
I agree, although I've been hoping "any day now" for the past few months haha
I'm getting really fed up with this whole "silence is golden" approach :(
Hey Brad, I'm curious about your POV now that we're less than month away from year-end. Are you confident Missling will deliver on his promise to shareholders and initiate all 3 trials as planned? I want to be confident, but we were also originally told we could expected a Rett trial by Q1 2017. If FDA developments result in a delay, that's fine, but it's the lack of transparency and communication with investors that's causing me concern.
You're spot on, Ria. Management will need to be more transparent with shareholders unless they want to continue this slow bleed into the 2s. It's almost insulting when the only news investors receive as of late is an update on a preliminary mouse study yet again. That's obviously not what the market wants and it shows. I've been long for over 2 years but am getting real tired of this "silence is golden" approach. Communication is key.
With all due respect Xena, I think the market is just fed up with Missling's deafening silence and lack of transparency to shareholders.
Some huge buys coming in...great volume! Wasn't expecting such an abrupt increase this week. Should hear about the NamasteMD app submission any day now, and hopefully an LP approval update by year-end!
Thanks so much for your input - I agree with your points! I guess my main concern at this point is more so around Amazon selling vaporizers and accessories at a more attractive price than its competitors. I understand selling cannabis itself is a whole different challenge. Namaste will soon offer consumers added convenience through its "one-stop shop" CannMart platform, but if Amazon can offer significantly lower prices on vaporizers and accessories, I worry that this could still pose a serious threat. Thanks again
Hey guys, just a quick question I've been struggling with lately that I was hoping to get some thoughts on. How would Namaste's sales be affected if an existing online giant like Amazon were to make a big entrance into the vaporizer space? Thanks in advance!
We've got about 30 business days left this year for Missling to deliver on his word...getting a little tired of watching this slow daily bleed. 2017 has been a pretty uneventful year for the company in the grand scheme of things. I've made sure to temper my expectations with past events like CTAD and various healthcare conferences, but I am 100% expecting significant trial news before year-end. I understand the FDA might be holding up the process, but the company owes its shareholders some form of update at the bare minimum. If there's nothing but silence from now until December 31st, I will definitely reconsider my investment strategy.
If the best argument against Anavex is still the tired old thrifty printing accusation, the company must be doing something right. I'm shocked more people don't understand how OTC tickers can be acquired.
Thanks attila!
September 11th at 10:00am
Doesn't look like we're in the program from what I'm seeing. I guess there's always the possibility of a late breaking presentation...
Lol come on guys. We're all hoping it means something but "0ct 2nd" is quite the stretch...
I hear you. I just worry how much our share price will continue to erode in the meantime. I understand many confident longs intend to hold unless the data indicates otherwise, but I can't say the same about institutional investors who grow increasingly impatient each day we remain silent.
Honestly, don't get your hopes up. We've been waiting for SOME kind of update for months now and haven't heard a peep. I'm getting tired of playing this "maybe news tomorrow" game :(
I'll be honest - yes, my patience is running thin...which is rare considering this is the first time in 2.5 years as an Anavex investor that I've felt this way. Missling owes shareholders an update, plain and simple.